ESA IV administration, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 173 431 40.2%
AusNZ D2(2002)
D3(2006) 411 458 88.8%
D3(2007) 367 422 88.3%
D4(2010) 174 221 82.2%
Belgium D2(2002) 396 500 77.1%
D3(2006) 464 468 99.3%
D3(2007) 365 373 97.9%
D4(2010) 388 390 99.4%
Canada D2(2002) 187 534 39.5%
D3(2006) 444 505 90.9%
D3(2007) 355 415 90.1%
D4(2010) 235 267 88.1%
France D2(2002) 203 423 54.5%
D3(2006) 426 486 88.8%
D3(2007) 441 483 90.8%
D4(2010) 259 283 91.1%
Germany D2(2002) 438 494 85.8%
D3(2006) 501 511 98.4%
D3(2007) 552 560 98.7%
D4(2010) 433 437 99.0%
Italy D2(2002) 150 497 30.9%
D3(2006) 402 443 91.6%
D3(2007) 411 454 91.1%
D4(2010) 326 349 92.7%
Japan D2(2002) 1,469 1,472 99.8%
D3(2006) 1,501 1,504 99.8%
D3(2007) 1,532 1,535 99.8%
D4(2010) 1,279 1,281 99.8%
Spain D2(2002) 282 556 53.5%
D3(2006) 593 601 98.7%
D3(2007) 489 497 97.9%
D4(2010) 457 464 98.5%
Sweden D2(2002) 250 510 44.4%
D3(2006) 355 501 68.1%
D3(2007) 359 467 77.9%
D4(2010) 242 370 67.5%
UK D2(2002) 120 510 19.4%
D3(2006) 227 392 55.0%
D3(2007) 208 312 56.5%
D4(2010) 197 311 61.3%
US D2(2002) 1,820 2,013 90.3%
D3(2006) 1,553 1,620 95.7%
D3(2007) 1,148 1,197 96.3%
D4(2010) 2,667 2,720 98.9%

Among patients prescribed any ESA

Please see additional methodological information in the Data Sources and Methods section.